Literature DB >> 11169153

Hepatocellular carcinoma arising in non-alcoholic steatohepatitis.

Y Zen1, K Katayanagi, K Tsuneyama, K Harada, I Araki, Y Nakanuma.   

Abstract

The incidence and significance of hepatocellular carcinoma (HCC) in non-alcoholic steatohepatitis (NASH) has not been previously evaluated in detail. We recently experienced a case of NASH with multicentric HCC in a female patient. At the age of 58 years, the patient was diagnosed with non-insulin-dependent diabetes mellitus, treated by insulin therapy. The patient did not drink alcohol. She was negative for all serological markers of hepatitis B and C virus infection. Because of liver dysfunction, a needle biopsy was performed at the age of 62 years, and pathological findings, such as fatty change, Mallory's body, nuclear glycogen and pericellular fibrosis, suggested a diagnosis of NASH. Subsequently, four nodules were detected in the liver by imaging. Liver biopsies were performed from each nodule. One nodule was pathologically diagnosed as a pseudolymphoma, while three other nodules were moderately differentiated HCC (10 years after the diagnosis of non-alcoholic steatohepatitis), well-differentiated HCC (11 years later) and dysplastic nodule (11 years later), suggesting multicentric occurrence of HCC. This case suggests that HCC could be a late complication of NASH.

Entities:  

Mesh:

Year:  2001        PMID: 11169153     DOI: 10.1046/j.1440-1827.2001.01174.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  36 in total

1.  Surgical outcomes for hepatocellular carcinoma in nonalcoholic fatty liver disease.

Authors:  Toshifumi Wakai; Yoshio Shirai; Jun Sakata; Pavel Vladimirovich Korita; Yoichi Ajioka; Katsuyoshi Hatakeyama
Journal:  J Gastrointest Surg       Date:  2011-04-22       Impact factor: 3.452

2.  Non-alcoholic fatty liver disease: is iron relevant?

Authors:  Julia O'Brien; Lawrie W Powell
Journal:  Hepatol Int       Date:  2011-08-12       Impact factor: 6.047

Review 3.  Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review.

Authors:  Yoshitaka Takuma; Kazuhiro Nouso
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

4.  Investigation of genome instability in patients with non-alcoholic steatohepatitis.

Authors:  Hatice Karaman; Ahmet Karaman; Hamiyet Donmez-Altuntas; Nazmiye Bitgen; Zuhal Hamurcu; Arzu Oguz; Cigdem Karakukcu
Journal:  World J Gastroenterol       Date:  2013-08-28       Impact factor: 5.742

Review 5.  Clinical review of nonalcoholic steatohepatitis in liver surgery and transplantation.

Authors:  Amit D Tevar; Calissia Clarke; Jiang Wang; Steven M Rudich; E Steve Woodle; Alex B Lentsch; Michael L Edwards
Journal:  J Am Coll Surg       Date:  2010-04       Impact factor: 6.113

6.  Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women.

Authors:  Juhua Luo; Rowan Chlebowski; Simin Liu; Katherine A McGlynn; Niyati Parekh; Donna L White; Karen L Margolis
Journal:  Cancer Causes Control       Date:  2012-05-24       Impact factor: 2.506

7.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

Review 8.  Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis.

Authors:  Shivakumar Chitturi; Jacob George
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 9.  Screening for hepatocellular carcinoma: why, when, how?

Authors:  Miguel R Arguedas
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 10.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.